Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate everolimus as second-line therapy in patients with metastatic renal
cell carcinoma. Each patient will be enrolled and stratified in one of three cohorts based
upon their first-line therapy: 1) prior cytokines, 2) prior sunitinib, or 3) prior anti-VEGF
therapy other than sunitinib.